Design and Development of Pi-Pi Staple Peptides Targeting Alpha-Synuclein for Parkinson’s Treatment
Disciplines
Medicinal-Pharmaceutical Chemistry | Organic Chemistry
Abstract (300 words maximum)
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by pathological aggregation of α-synuclein, an intrinsically disordered protein. Peptide-based inhibitors offer a promising therapeutic strategy to block α-synuclein aggregation. This study aimed to design, synthesize, and evaluate peptide candidates with inhibitory potential. Twelve peptides were initially screened from SynPEP-DB using molecular docking to predict binding interactions with α-synuclein. Five top candidates with favorable docking scores were synthesized via solid-phase peptide synthesis (SPPS) and characterized by LC-MS. Binding affinities were quantified using selected ion monitoring mass spectrometry (SIM-MS), which confirmed strong peptide–protein interactions. Three peptides showed nanomolar affinity with dissociation constants (Kd) of 22.98, 63.53, and 65.57 nM. Structural analogs were also evaluated, and an α-methylated peptide exhibited the strongest binding (Kd = 21.49 nM). On the other hand, α-synuclein fibril reduction was evaluated using the Thioflavin T fluorescence assay. The α-methylated analogue exhibited a significant 89.2% reduction in fibril formation, compared to other top candidates showing reductions ranging from 66.6% to 87.8%. These findings validate computational predictions and demonstrate that methylation effectively enhances peptide activity. This integrated computational–experimental approach provides a rational framework for peptide drug discovery targeting α-synuclein aggregation. The combined SIM-MS and ThT fluorescence results offer proof-of-concept that α-methylation improves fibril reduction, supporting the potential of pi-pi staple peptides as inhibitors of α-synuclein aggregation for Parkinson’s disease (PD)Treatment. Future work will aim to further enhance peptide stability and activity through structural modifications such as cyclization and targeted methylation.
Use of AI Disclaimer
no
Academic department under which the project should be listed
CSM – Chemistry and Biochemistry
Primary Investigator (PI) Name
Mohammad Halim
Oral Presentation
Design and Development of Pi-Pi Staple Peptides Targeting Alpha-Synuclein for Parkinson’s Treatment
Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by pathological aggregation of α-synuclein, an intrinsically disordered protein. Peptide-based inhibitors offer a promising therapeutic strategy to block α-synuclein aggregation. This study aimed to design, synthesize, and evaluate peptide candidates with inhibitory potential. Twelve peptides were initially screened from SynPEP-DB using molecular docking to predict binding interactions with α-synuclein. Five top candidates with favorable docking scores were synthesized via solid-phase peptide synthesis (SPPS) and characterized by LC-MS. Binding affinities were quantified using selected ion monitoring mass spectrometry (SIM-MS), which confirmed strong peptide–protein interactions. Three peptides showed nanomolar affinity with dissociation constants (Kd) of 22.98, 63.53, and 65.57 nM. Structural analogs were also evaluated, and an α-methylated peptide exhibited the strongest binding (Kd = 21.49 nM). On the other hand, α-synuclein fibril reduction was evaluated using the Thioflavin T fluorescence assay. The α-methylated analogue exhibited a significant 89.2% reduction in fibril formation, compared to other top candidates showing reductions ranging from 66.6% to 87.8%. These findings validate computational predictions and demonstrate that methylation effectively enhances peptide activity. This integrated computational–experimental approach provides a rational framework for peptide drug discovery targeting α-synuclein aggregation. The combined SIM-MS and ThT fluorescence results offer proof-of-concept that α-methylation improves fibril reduction, supporting the potential of pi-pi staple peptides as inhibitors of α-synuclein aggregation for Parkinson’s disease (PD)Treatment. Future work will aim to further enhance peptide stability and activity through structural modifications such as cyclization and targeted methylation.